Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Morphometric assessment
All CELs (n = 54) Gliomas (n = 38) Metastases (n = 16)
TV (median/IQR) (mL) 
    MPRAGE 1.36/0.18–10.93 3.02/0.44–28.93 0.33/0.006–2.81
    SPACE 1.78/0.20–11.00 3.5/0.49–29.73 0.39/0.006–3.2
    VIBE 1.62/0.16–10.35 3.39/0.43–27.48 0.40/0.007–2.84
TV, SPACE vs MPRAGE 
    P^{^a} .001^{^b} .007^{^b} .003^{^b}
    P (adjusted for sequence acquisition order)^{^c} .034^{^b} .033^{^b} .075
TV, VIBE vs MPRAGE 
    P^{^a} .259 .201 .343
    P (adjusted for sequence acquisition order)^{^c} .521 .538 .706
MED (median/% of TV) 
    |CEL_MPRAGE|–|CEL_SPACE| 0.10 mL/7.4% 0.18 mL/6% 0.02 mL/6.1%
    |CEL_SPACE|–|CEL_MPRAGE| 0.27 mL/19.9% 0.43 mL/14.2% 0.05 mL/15.2%
    |CEL_MPRAGE|–|CEL_VIBE| 0.15 mL/11% 0.21 mL/7% 0.01 mL/3%
    |CEL_VIBE|–|CEL_MPRAGE| 0.15 mL/11% 0.23 mL/7.6% 0.05 mL/15.2%
Note:—MED indicates margin extent discrepancy; IQR, interquartile range.
↵a Wilcoxon signed rank test.
↵b Statistically significant differences.
↵c General Linear Model.

	All CELs (n = 54)	Gliomas (n = 38)	Metastases (n = 16)
TV (median/IQR) (mL)
MPRAGE	1.36/0.18–10.93	3.02/0.44–28.93	0.33/0.006–2.81
SPACE	1.78/0.20–11.00	3.5/0.49–29.73	0.39/0.006–3.2
VIBE	1.62/0.16–10.35	3.39/0.43–27.48	0.40/0.007–2.84
TV, SPACE vs MPRAGE
P^{^a}	.001^{^b}	.007^{^b}	.003^{^b}
P (adjusted for sequence acquisition order)^{^c}	.034^{^b}	.033^{^b}	.075
TV, VIBE vs MPRAGE
P^{^a}	.259	.201	.343
P (adjusted for sequence acquisition order)^{^c}	.521	.538	.706
MED (median/% of TV)
\|CEL_MPRAGE\|–\|CEL_SPACE\|	0.10 mL/7.4%	0.18 mL/6%	0.02 mL/6.1%
\|CEL_SPACE\|–\|CEL_MPRAGE\|	0.27 mL/19.9%	0.43 mL/14.2%	0.05 mL/15.2%
\|CEL_MPRAGE\|–\|CEL_VIBE\|	0.15 mL/11%	0.21 mL/7%	0.01 mL/3%
\|CEL_VIBE\|–\|CEL_MPRAGE\|	0.15 mL/11%	0.23 mL/7.6%	0.05 mL/15.2%